

Patent
Attorney's Docket No. 032915-005

#15
JLP
2/1/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Roger LORIA

Application No.: 09/255,499

Filed: January 6, 1999

For: 5-ANDROSTENE-3 β , 17 α -DIOL AS AN
INHIBITOR OF TUMOR GROWTH



Group Art Unit: 1614

Examiner: J. Goldberg

JAN 29 2001
TECH CENTER 1600/2900

RECEIVED

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, applicant hereby submits the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: Malcolm K. McGowan

Malcolm K. McGowan, Ph.D.
Registration No. 39,300

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: January 24, 2001